Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct:99:107968.
doi: 10.1016/j.intimp.2021.107968. Epub 2021 Jul 10.

"Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study."

Dinesh Joshi  1 , Kamal Sharma  1 , Senthilraj Thangasami  2 , Rahul Patel  1 , Iva Patel  1
Affiliations

"Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study."

Dinesh Joshi et al. Int Immunopharmacol. 2021 Oct.

Abstract

Background: The current COVID-19 pandemic has become a global public health crisis and presents a serious challenge in treatment of severe COVID pneumonia patients. With an imperative need for an effective treatment, we aimed to study the effectiveness of Pentaglobin, an intravenous immunoglobin in the treatment of severe Covid-19 pneumonia patients.

Methods: This is an open-label non-randomised controlled study. Patients in the study group (n = 17) received Pentaglobin in addition to standard therapy and the control group (n = 19) received only the standard of care treatment. Severity of illness were quantified by severity scores and inflammatory laboratory parameters were compared between the two groups.

Results: The average length of hospital stay in pentaglobin group were 12.35 ± 6.98 days compared to 10.94 ± 4.62 days in standard treatment group with mean difference of 1.4 days (p value = 0.4). Pentaglobin did not provide an added advantage in terms of reducing the duration of hospital stay. There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86). CT Severity score (OR = 1.39 95% CI = 1.09-1.77, P = 0.01), APACHE II score (OR = 1.16 95% CI = 0.99-1.35, P = 0.05) and the SOFA score (OR = 2.11 95% CI = 1.13-3.93, P = 0.02) were independent predictors of mortality.

Conclusion: The administration of pentaglobin in COVID -19 patients has no significant effect in reducing the risk of mechanical ventilation or death, in disease worsening or in reduction of inflammation.

Keywords: COVID-19; Immunomodulation; Pentaglobin; SAR-COV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

References

    1. Helmy Y.A., Fawzy M., Elaswad A., Sobieh A., Kenney S.P., Shehata A.A. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Journal of clinical medicine. 2020 Apr;9(4):1225. - PMC - PubMed
    1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio.... Accessed on date 24-03-2021.
    1. Sharma D., Sharma N., Sharma P., Subramaniam G. Review of investigational drugs for coronavirus disease 2019. J of Education and Health Promotion. 2021;10 - PMC - PubMed
    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. Jama. 2020 Aug 25;324(8):782–793. - PubMed
    1. Cui J., Wei X., Lv H., Li Y., Li P., Chen Z., Liu G. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Annals of intensive care. 2019 Dec;9(1):1–4. - PMC - PubMed